MX2011012047A - Inmunoglobulinas humanas anti-cd52. - Google Patents

Inmunoglobulinas humanas anti-cd52.

Info

Publication number
MX2011012047A
MX2011012047A MX2011012047A MX2011012047A MX2011012047A MX 2011012047 A MX2011012047 A MX 2011012047A MX 2011012047 A MX2011012047 A MX 2011012047A MX 2011012047 A MX2011012047 A MX 2011012047A MX 2011012047 A MX2011012047 A MX 2011012047A
Authority
MX
Mexico
Prior art keywords
humanized
humanized immunoglobulin
immunoglobulins
relates
human
Prior art date
Application number
MX2011012047A
Other languages
English (en)
Spanish (es)
Inventor
Bruce L Roberts
William M Siders
Srinivas Shankara
William Harold Brondyk
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43085579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011012047(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2011012047A publication Critical patent/MX2011012047A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
MX2011012047A 2009-05-13 2010-05-13 Inmunoglobulinas humanas anti-cd52. MX2011012047A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17783709P 2009-05-13 2009-05-13
PCT/US2010/034704 WO2010132659A2 (en) 2009-05-13 2010-05-13 Anti-human cd52 immunoglobulins

Publications (1)

Publication Number Publication Date
MX2011012047A true MX2011012047A (es) 2011-12-14

Family

ID=43085579

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012047A MX2011012047A (es) 2009-05-13 2010-05-13 Inmunoglobulinas humanas anti-cd52.

Country Status (19)

Country Link
US (5) US8617554B2 (OSRAM)
EP (3) EP3683317A3 (OSRAM)
JP (4) JP5894912B2 (OSRAM)
KR (5) KR20160005143A (OSRAM)
CN (3) CN102459628A (OSRAM)
AR (1) AR076770A1 (OSRAM)
AU (1) AU2010249003B2 (OSRAM)
BR (1) BRPI1013085A2 (OSRAM)
CA (2) CA2939492C (OSRAM)
HK (2) HK1222682A1 (OSRAM)
IL (2) IL216141B (OSRAM)
MX (1) MX2011012047A (OSRAM)
MY (1) MY160126A (OSRAM)
NZ (2) NZ621170A (OSRAM)
RU (2) RU2016142225A (OSRAM)
SG (2) SG176060A1 (OSRAM)
TW (3) TWI529247B (OSRAM)
WO (1) WO2010132659A2 (OSRAM)
ZA (1) ZA201108077B (OSRAM)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2300022A2 (en) 2008-04-25 2011-03-30 Duke University Regulatory b cells and their uses
CN102438654A (zh) 2009-05-13 2012-05-02 基酶有限公司 治疗狼疮的方法和组合物
NZ621170A (en) * 2009-05-13 2015-08-28 Genzyme Corp Anti-human cd52 immunoglobulins
WO2012088272A1 (en) * 2010-12-21 2012-06-28 Duke University Methods and compositions combining immunotherapy with monocyte activation
JP6104794B2 (ja) 2011-04-18 2017-03-29 国立大学法人 東京大学 抗ｉｔｍ２ａ抗体を用いる癌の診断および治療
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
KR102096224B1 (ko) 2011-10-28 2020-04-03 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 폴리펩티드 구축물 및 이의 용도
WO2013185165A1 (en) * 2012-06-14 2013-12-19 The Walter And Eliza Hall Institute Of Medical Research Cd-52 antibodies and their use in determining and enhancing an immune response in a subject
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
US20150299315A1 (en) * 2012-10-22 2015-10-22 Becton, Dickinson And Company Non-b-lineage cells capable of producing antibody
WO2014165282A1 (en) 2013-03-12 2014-10-09 Institute of Arthritis Research, LLC Immunologically active polypeptide
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
AR095199A1 (es) * 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
KR102042174B1 (ko) 2013-03-29 2019-11-08 삼성전자주식회사 인간화 및 친화도 성숙된 항 ｃ-Ｍｅｔ 항체 및 그의 용도
KR102060540B1 (ko) * 2013-04-03 2019-12-31 삼성전자주식회사 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물
SG11201508358RA (en) 2013-04-09 2015-11-27 Boston Biomedical Inc 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
KR102186363B1 (ko) * 2013-09-06 2020-12-04 삼성전자주식회사 c-Met 저해제 및 베타-카테닌 저해제를 포함하는 병용 투여용 약학 조성물
KR102192591B1 (ko) * 2013-09-09 2020-12-18 삼성전자주식회사 c-Met 저해제 및 c-Myc 저해제를 포함하는 병용 투여용 약학 조성물
US20180140572A1 (en) 2015-06-03 2018-05-24 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
US10752679B2 (en) 2016-05-02 2020-08-25 Prothena Biosciences Limited Tau immunotherapy
PE20190208A1 (es) 2016-05-02 2019-02-07 Prothena Biosciences Ltd Anticuerpos que reconocen tau
EP3452508A1 (en) 2016-05-02 2019-03-13 Prothena Biosciences Limited Antibodies recognizing tau
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
EP3554515A4 (en) 2016-12-15 2020-08-26 Duke University B10 REGULATORY CELL DEPLETION ANTIBODIES AND METHODS AND THEIR USE IN COMBINATION WITH IMMUNITY CHECKPOINT INHIBITORS
JP7219721B2 (ja) * 2017-04-21 2023-02-08 ジェンザイム・コーポレーション 抗ｃｄ５２抗体を用いて多発性硬化症を処置するための経路およびスケジュール
MX2019013045A (es) 2017-05-02 2020-02-12 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
GB201710836D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
EP3728301A4 (en) * 2017-12-20 2021-10-06 Radimmune Therapeutics, Inc. ANTIBODIES DIRECTED AGAINST CENTRIN-1, THEIR MANUFACTURING PROCESSES AND THEIR USES
EP4292659A3 (en) * 2018-12-19 2024-03-20 Humabs Biomed SA Antibodies that neutralize hepatitis b virus and uses thereof
HRP20231338T1 (hr) 2018-12-20 2024-02-16 Vir Biotechnology, Inc. Kombinirana terapija hbv
AU2020231366A1 (en) 2019-03-03 2021-08-12 Prothena Biosciences Limited Antibodies recognizing tau
CN109929835A (zh) * 2019-03-27 2019-06-25 中国人民解放军第四军医大学 一种鼠单克隆抗体功能轻链可变区基因的扩增方法
EP3972998A1 (en) 2019-05-21 2022-03-30 Novartis AG Cd19 binding molecules and uses thereof
WO2021000017A1 (en) * 2019-07-02 2021-01-07 Telix International Pty Ltd Antibodies against caix with reduced affinity for the neonatal fc receptor
CN115515984A (zh) * 2020-05-08 2022-12-23 亘喜生物科技（上海）有限公司 一种抗cd19抗体的抗体及其制备和应用
KR20230109683A (ko) * 2020-11-19 2023-07-20 젠자임 코포레이션 유세포 분석 감쇠 리포터 발현(플레어) 다중 리포터 시스템 및 이의 사용 방법
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
WO2025031965A1 (en) * 2023-08-04 2025-02-13 Cimeio Therapeutics Ag Discernible cell surface protein variants of cd52 for use in cell therapy

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1987006265A1 (fr) 1986-04-17 1987-10-22 Kyowa Hakko Kogyo Co., Ltd. Nouveaux composes dc-88a et dc-89a1, et procede pour leur preparation
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
DE68909441T2 (de) * 1988-02-12 1994-02-10 British Tech Group Modifizierte Antikörper.
JP2598116B2 (ja) 1988-12-28 1997-04-09 協和醗酵工業株式会社 新規物質ｄｃ１１３
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5187186A (en) 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
JP2510335B2 (ja) 1989-07-03 1996-06-26 協和醗酵工業株式会社 Ｄｃ―８８ａ誘導体
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9022547D0 (en) 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
GB9108056D0 (en) * 1991-04-16 1991-06-05 Hale Geoffrey Synthetic antigen
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5269388A (en) 1991-11-12 1993-12-14 Stress-Tek, Inc. Weighing bed
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US7119248B1 (en) 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
ATE271557T1 (de) 1994-04-22 2004-08-15 Kyowa Hakko Kogyo Kk Dc-89 derivat
US5550246A (en) 1994-09-07 1996-08-27 The Scripps Research Institute Calicheamicin mimics
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
GB9603507D0 (en) 1996-02-20 1996-04-17 Isis Innovation Antibody variants
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
ATE319745T1 (de) 1997-05-21 2006-03-15 Biovation Ltd Verfahren zur herstellung von nicht-immunogenen proteinen
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
CA2388063C (en) 1999-11-24 2010-06-08 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
NZ521182A (en) 2000-03-03 2004-11-26 Cambridge Antibody Tech Human antibodies against eotaxin comprising VH adn VL domains and their use
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
US20020132983A1 (en) 2000-11-30 2002-09-19 Junghans Richard P. Antibodies as chimeric effector cell receptors against tumor antigens
ATE395413T1 (de) 2001-12-03 2008-05-15 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
US20050191632A1 (en) 2002-11-01 2005-09-01 John Byrd Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia
CN1225480C (zh) * 2002-12-18 2005-11-02 马菁 抗cd52单克隆抗体、其编码序列及应用
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
WO2004087210A1 (ja) 2003-03-31 2004-10-14 Kirin Beer Kabushiki Kaisha 抗cd52抗体による調節性t細胞分化誘導･増殖方法およびそのための医薬組成物
US7709224B2 (en) 2003-06-03 2010-05-04 Biosante Pharmaceuticals, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
CN1898267B (zh) * 2003-11-01 2012-05-23 默克专利股份有限公司 修饰的抗cd52抗体
US20060204496A1 (en) 2003-11-28 2006-09-14 Tetsuo Kojima Agonist antibody against heteroreceptor
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
KR101247908B1 (ko) * 2004-09-02 2013-03-26 제넨테크, 인크. 항-ｆｃ-감마 ｒｉｉｂ 수용체 항체 및 그의 용도
EP1850873B1 (en) 2005-02-08 2018-11-28 Genzyme Corporation Antibodies to tgfbeta
KR20080039843A (ko) * 2005-05-24 2008-05-07 아베스타 겐그레인 테크놀로지스 피브이티 리미티드 만성 림프구성 백혈병의 치료를 위한 ｃｄ52 에 대한모노클로날 항체의 제조를 위한 재조합 방법
CN102441163A (zh) 2005-05-27 2012-05-09 比奥根艾迪克Ma公司 结合tweak的抗体
WO2007076927A1 (en) * 2005-12-30 2007-07-12 Merck Patent Gmbh Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130
CA2649440A1 (en) * 2006-04-12 2007-10-25 Genzyme Corporation Methods of treating autoimmune diseases
ES2917882T3 (es) 2006-09-13 2022-07-12 Alcafleu Man Gmbh & Co Kg Tratamiento de esclerosis múltiple (MS) con Campath-1H
AU2008219681A1 (en) 2007-02-28 2008-09-04 Merck Sharp & Dohme Corp. Combination therapy for treatment of immune disorders
CA2689408A1 (en) * 2007-06-22 2008-12-31 Bayer Schering Pharma Aktiengesellschaft Use of antibodies against the cd52 antigen for the treatment of neurological disorders, particularly transmissible spongiform encephalopathy and alzheimer's disease
CN102438654A (zh) 2009-05-13 2012-05-02 基酶有限公司 治疗狼疮的方法和组合物
NZ621170A (en) 2009-05-13 2015-08-28 Genzyme Corp Anti-human cd52 immunoglobulins
EP2429584A4 (en) 2009-05-13 2013-02-20 Genzyme Corp TREATMENT PROCEDURE AND COMPOSITIONS
CN102666583B (zh) 2009-07-15 2015-11-25 Aimm医疗股份公司 革兰氏阳性细菌特异性结合化合物
EP3336225B1 (en) 2010-07-16 2020-02-19 Adimab, LLC Antibody libraries
ITMI20110376A1 (it) 2011-03-10 2012-09-11 Wilic Sarl Aerogeneratore raffreddato a fluido
GB201109238D0 (en) 2011-06-01 2011-07-13 Antitope Ltd Antibodies
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
CN108025083B (zh) 2014-10-09 2021-09-03 建新公司 糖工程化的抗体药物缀合物
JP7219721B2 (ja) 2017-04-21 2023-02-08 ジェンザイム・コーポレーション 抗ｃｄ５２抗体を用いて多発性硬化症を処置するための経路およびスケジュール

Also Published As

Publication number Publication date
RU2011150516A (ru) 2013-06-20
BRPI1013085A2 (pt) 2020-11-03
AU2010249003B2 (en) 2015-08-20
KR20160103160A (ko) 2016-08-31
EP2998405A1 (en) 2016-03-23
SG176060A1 (en) 2011-12-29
EP3683317A3 (en) 2020-09-30
JP2012526558A (ja) 2012-11-01
US20120100152A1 (en) 2012-04-26
TWI529247B (zh) 2016-04-11
CN104231084B (zh) 2019-04-23
SG10201608169QA (en) 2016-11-29
CA2939492C (en) 2019-03-19
HK1205152A1 (en) 2015-12-11
HK1222682A1 (en) 2017-07-07
MY160126A (en) 2017-02-28
IL216141A0 (en) 2012-01-31
CN110016081A (zh) 2019-07-16
JP5894912B2 (ja) 2016-03-30
JP2014195474A (ja) 2014-10-16
CA2939492A1 (en) 2010-11-18
AU2010249003A1 (en) 2011-11-03
RU2016142225A (ru) 2018-12-18
AR076770A1 (es) 2011-07-06
ZA201108077B (en) 2013-01-30
CN102459628A (zh) 2012-05-16
TW201043694A (en) 2010-12-16
CN104231084A (zh) 2014-12-24
NZ596384A (en) 2014-03-28
TW201636367A (zh) 2016-10-16
CA2761800C (en) 2016-09-27
US8617554B2 (en) 2013-12-31
JP2018029624A (ja) 2018-03-01
IL262639A (en) 2018-12-31
CA2761800A1 (en) 2010-11-18
JP2016093194A (ja) 2016-05-26
US11945874B2 (en) 2024-04-02
KR101537840B1 (ko) 2015-07-22
EP3683317A2 (en) 2020-07-22
WO2010132659A2 (en) 2010-11-18
EP2998405B1 (en) 2019-12-11
EP2429582A2 (en) 2012-03-21
NZ621170A (en) 2015-08-28
WO2010132659A3 (en) 2011-01-06
TWI614267B (zh) 2018-02-11
KR20140102764A (ko) 2014-08-22
US20220010024A1 (en) 2022-01-13
TW201825115A (zh) 2018-07-16
RU2603743C2 (ru) 2016-11-27
EP2429582A4 (en) 2013-01-23
US20140341910A1 (en) 2014-11-20
KR20120111932A (ko) 2012-10-11
US20160208010A1 (en) 2016-07-21
US20200040091A1 (en) 2020-02-06
KR20160005143A (ko) 2016-01-13
KR20170113704A (ko) 2017-10-12
IL216141B (en) 2018-11-29

Similar Documents

Publication Publication Date Title
MX2011012047A (es) Inmunoglobulinas humanas anti-cd52.
ZA202109042B (en) Methods of reducing serum levels of fc-containing agents using fcrn antagonists
PH12013500990A1 (en) Neutralizing anti-ccl20 antibodies
UA117901C2 (uk) Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
SA519410565B1 (ar) (ctla-4)أجسام مضادة أحادية النسيلة جديدة لبروتين مرتبط بخلية ليمفاوية تائية سامة للخلايا 4
SG10201906762YA (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
WO2020069184A3 (en) Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
JP2014518615A5 (OSRAM)
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
RU2010129045A (ru) Связывающие молекулы к рецептору ох40 человека
RU2014108208A (ru) Мыши с гуманизированной универсальной легкой цепью
MX2009003838A (es) Anticuerpos anti-cd20 y metodos de uso.
NZ706004A (en) Antibodies for treatment of cancer expressing claudin 6
UA114879C2 (uk) Антитіло до cd38 для лікування раку
RU2014144143A (ru) Химерные антигенные рецепторы, нацеленные на антиген созревания в-клеток
Hristodorov et al. Recombinant H22 (scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody: A potential strategy to enhance anti-TNF therapy
MX2021008672A (es) Competidores de cd31 y usos de los mismos.
RU2019100102A (ru) Гуманизированные и химерные моноклональные антитела против cd81
JP2019517813A5 (OSRAM)
TH143301A (th) นิวทรอลไลซ์ซิ่ง แอนติ-CCL-20 แอนติบอดี้ (NEUtralizing Anti-CCL-20 Antibodies)
NZ810163A (en) Mice that make binding proteins comprising vl domains
NZ769571A (en) Antibodies binding pd-1 and uses thereof
HK1189899A (en) Neutralizing anti-ccl20 antibodies
NZ780754A (en) Antigen-binding proteins that activate the leptin receptor
NZ780754B2 (en) Antigen-binding proteins that activate the leptin receptor

Legal Events

Date Code Title Description
FG Grant or registration